Arrhythmogenic Cardiomyopathy is an Inflammatory Disease
致心律失常性心肌病是一种炎症性疾病
基本信息
- 批准号:10132387
- 负责人:
- 金额:$ 50.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse eventAgonistAllelesAnti-Inflammatory AgentsApoptosisArrhythmiaAutomobile DrivingCardiacCardiac MyocytesCellsChronicClinicalClinical TrialsDangerousnessDataDevelopmentDiseaseDisease ProgressionEventExerciseFDA approvedFunctional disorderFutureGoalsHeartImmuneImmune responseIn VitroInflammationInflammation MediatorsInflammatoryInflammatory InfiltrateInjuryInnate Immune ResponseInterleukin-1 betaMalignant NeoplasmsMediatingMicroRNAsMusMuscle CellsMyocarditisPathogenesisPathway interactionsPatientsPenetrancePharmaceutical PreparationsPharmacotherapyPlayPreclinical TestingProductionRNAReportingResearchRiskRoleSignal PathwaySignal TransductionSudden DeathTestingTherapeuticVentricularWorkarrhythmogenic cardiomyopathybasecardiac muscle diseasedisease phenotypeeffective therapyefficacy testingexercise trainingexperimental studygenetic approachglycogen synthase kinase 3 betaheuristicsimmune activationin vivo Modelinduced pluripotent stem cellinhibitor/antagonistinsightmouse modelmyocardial damagemyocardial injurynew therapeutic targetpre-clinicalpreventsmall moleculetargeted treatment
项目摘要
Project Summary/Abstract
The goal of this project is to define the role of inflammation in the pathogenesis of arrhythmogenic
cardiomyopathy (ACM), a familial non-ischemic heart muscle disease that causes sudden death in the young
and especially in athletes. Exercise accelerates disease penetrance, and increases arrhythmic risk and
adverse cardiac events in ACM patients, but how exercise exacts this terrible toll is not known. We now report
substantial new data showing that ACM disease alleles activate NFκB signaling in cardiac myocytes and that
inhibition of this signaling pathway prevents the full ACM disease phenotype in a robust, well characterized
mouse model. We also show that exercise greatly intensifies inflammatory signaling, thus providing a new
mechanistic explanation for accelerated disease progression in athletes. These observations suggest that
targeted anti-inflammatory therapy could be a powerful, truly mechanism-based approach to reduce adverse
events in ACM patients. Accordingly, we will test the hypotheses that 1) activation of an innate immune
response in cardiac myocytes mediated by NFκB causes arrhythmias and myocardial damage in ACM; and 2)
exercise accelerates progression of ACM by stimulating production of injurious inflammatory mediators via
activation of NFκB signaling in cardiac myocytes. In Aim 1, we will use genetic approaches in defined mouse
models to elucidate the relative contributions to the ACM disease phenotype of activation of an immune
response in cardiac myocytes vs. the actions of infiltrating inflammatory cells. In Aim 2, we will characterize
effects of exercise on inflammation in ACM and define new mechanisms by which exercise promotes
myocardial injury and arrhythmias. And in Aim 3, we will test the efficacy of selected FDA-approved drugs to
prevent clinically important features of the ACM disease phenotype and mitigate the dangerous effects of
exercise. We will also characterize expression of miRNAs that regulate NFκB and GSK3β signaling to identify
RNA-based strategies to turn off inflammatory signaling. Such preclinical testing, we hope, will provide a
pathway to future clinical trials in patients with ACM.
项目总结/摘要
该项目的目标是确定炎症在致炎性结肠炎发病机制中的作用,
心肌病(ACM),一种家族性非缺血性心肌疾病,可导致年轻人猝死
尤其是运动员。运动会加速疾病的消退,并增加患病的风险,
ACM患者的不良心脏事件,但运动如何导致这种可怕的代价尚不清楚。我们现在报告说
大量新数据显示ACM疾病等位基因激活心肌细胞中NFκB信号传导,
这种信号通路的抑制防止了完整的ACM疾病表型,
小鼠模型我们还表明,运动大大加强炎症信号,从而提供了一个新的
运动员疾病进展加速的机制解释。这些观察提示
靶向抗炎治疗可能是一种有效的,真正基于机制的方法,以减少不良反应。
ACM患者中发生的事件。因此,我们将测试以下假设:1)先天免疫的激活
在ACM中,由NFκB介导的心肌细胞反应导致心律失常和心肌损伤;和2)
运动通过刺激有害炎症介质的产生加速ACM的进展,
心肌细胞中NFκB信号的激活。在目标1中,我们将在定义的小鼠中使用遗传方法
模型来阐明免疫激活对ACM疾病表型的相对贡献,
心肌细胞的反应与浸润性炎症细胞的作用。在目标2中,我们将描述
运动对ACM炎症的影响,并确定运动促进ACM炎症的新机制。
心肌损伤和心律失常。在目标3中,我们将测试选定的FDA批准的药物的疗效,
预防ACM疾病表型的临床重要特征,并减轻
锻炼的我们还将描述调节NFκB和GSK 3 β信号传导的miRNA的表达,
基于RNA的策略来关闭炎症信号。我们希望,这样的临床前测试将提供一个
ACM患者未来临床试验的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY E SAFFITZ其他文献
JEFFREY E SAFFITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY E SAFFITZ', 18)}}的其他基金
Arrhythmogenic Cardiomyopathy is an Inflammatory Disease
致心律失常性心肌病是一种炎症性疾病
- 批准号:
10379358 - 财政年份:2020
- 资助金额:
$ 50.34万 - 项目类别:
Arrhythmogenic Cardiomyopathy is an Inflammatory Disease
致心律失常性心肌病是一种炎症性疾病
- 批准号:
10629180 - 财政年份:2020
- 资助金额:
$ 50.34万 - 项目类别:
Altered Cell-Cell Coupling in Arrhythmogenic Cardiomyopathy
致心律失常性心肌病中细胞间偶联的改变
- 批准号:
10202697 - 财政年份:2018
- 资助金额:
$ 50.34万 - 项目类别:
Determinants of Disease Expression in Arrhythmogenic Cardiomyopathy
致心律失常性心肌病疾病表达的决定因素
- 批准号:
7936263 - 财政年份:2009
- 资助金额:
$ 50.34万 - 项目类别:
Determinants of Disease Expression in Arrhythmogenic Cardiomyopathy
致心律失常性心肌病疾病表达的决定因素
- 批准号:
7826249 - 财政年份:2009
- 资助金额:
$ 50.34万 - 项目类别:
MECHANISMS OF ACCELERATED VASCULAR DISEASE IN DIABETES
糖尿病血管疾病加速发生的机制
- 批准号:
6338895 - 财政年份:2000
- 资助金额:
$ 50.34万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




